The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …

Cancer cells shed naked DNA molecules into the circulation. This circulating tumor DNA
(ctDNA) has become the predominant analyte for liquid biopsies to understand the …

Simple Summary Lung cancer patients with a specific gene mutation often undergo tissue
biopsies to guide treatment. But what if a simple blood test could do the same? This review …

Objective The study objective was to evaluate the impact of monitoring circulating tumor
DNA on the detection and management of recurrence in patients with resected early-stage …

Breast cancer is the most common cancer among women in the world as well as in the
United States. Molecular and histological differentiation have helped clinicians optimize …

Introduction Immunotherapy (IO) has transformed the treatment paradigm for a wide variety
of solid tumours. However, assessment of response can be challenging with conventional …

Advances in Next Generation Sequencing (NGS) technologies have enabled the accurate
detection and quantification of circulating tumor-derived (ct) DNA in most gastrointestinal …